Oliver Sartor, MD, discusses how unmet needs and clinical challenges for PSMA imaging in prostate cancer patients include standardizing interpretation criteria, addressing false negatives in certain tumor phenotypes, improving accessibility and cost-effectiveness, and developing strategies for patients with low PSMA expression or PSMA-negative disease.
"We were trying to understand how veterans were making decisions about germline testing for their prostate cancer," says Daniel Kwon, MD.
“I think this is the future, and if we don't go down that path and we don't explore, we're not going to make it better for us and for the patients,” says Geoffrey N. Sklar, MD, FACS.
"We were really surprised that we found that the anxiety components in the depression questions in those 3 questionnaires really improved drastically when we compared them to pretreatment vs post treatment," says Andrew C. Peterson, MD, MPH.
"For urologists that are interested in implementing Aquablation into their armamentarium, I am very envious, because anyone who is going to start doing Aquablation now is going to be using the HYDROS System," says Ravi Munver, MD.
"This is quite reassuring to show that there's no statistically significant influence of BMI in actual complications," says Muhammed A. Moukhtar Hammad, MBBCh.
“For us, being able to know where the cancer is allows us to target it, and I think that lets us be much more effective with our treatment,” says Bridget F. Koontz, MD, FASTRO.
Panelists discuss how some of the most critical challenges and unmet needs in the treatment and management of metastatic castration-sensitive prostate cancer (mCSPC) include the effectiveness of monotherapy, the need for better risk stratification, and the integration of novel therapies to improve patient outcomes.
"I think it would be really nice if we did have standardized guidelines on who could serve as a chaperone," says Ellen Cahill, MD.
"Patients, in general, have been extremely happy, and the one thing that I think keeps them happy is I'm continually evolving with how I give the information," says Michael Jenson, PA-C.
“There's not an increase of reimbursement across all provinces in Canada that met up or was at par with the cost-of-living index,” says Kevin C. Zorn, MD, FRCSC, FACS.
"Over a third of Americans actually use some kind of what we term complementary or alternative medicine approach," says Raevti Bole, MD.
“There are a lot of other ways to look at bel-sar with other immunotherapy agents, other combinations, to truly help prevent patients needing to go to the operating room,” says Gary D. Steinberg, MD.
"The 5-year data from STOMP showed that about a third of men could go 5 years without requiring ADT, which is exciting," says Bridget F. Koontz, MD, FASTRO.
Oliver Sartor, MD, discusses how 68gallium PSMA-11 PET is indeed the preferred imaging modality for confirming eligibility for lutetium therapy, but when unavailable, alternative options such as F-18 PSMA PET, conventional bone scintigraphy, or CT/MRI may be considered, albeit with potential limitations in sensitivity and specificity.
“We really need to do a better job of destigmatizing these conversations so guys are comfortable asking their providers [about sensitive health issues],” says Justin Dubin, MD.
“Now for muscle-invasive [disease], how I counsel patients on surgery when they're a man vs a woman is almost completely different, because their anatomy is very different,” says Ava Saidian, MD.
"We found actually that patients who underpredict their curve during the initial visit, prior to having a formal measurement of their penile curvature, actually ended up having a higher satisfaction following treatment," says Jake Miller, MD.
Panelists discuss how the increased use of androgen receptor–targeted therapy in clinical practice may impact the effectiveness of PARP inhibitor combinations like talazoparib in the TALAPRO-2 study, while also addressing safety concerns, potential differences in trial populations, and the need for future studies to optimize treatment approaches for various metastatic prostate cancer patient subgroups.
Panelists discuss how the PROfound trial (NCT02987543) demonstrated the efficacy and safety of olaparib monotherapy in metastatic prostate cancer patients with homologous recombination repair gene alterations, highlighting its potential as a targeted treatment option and its impact on the landscape of precision medicine in prostate cancer management.
Michael Jenson, PA-C, gives an overview of the Surgical Impotence Management Strategy program at Minnesota Urology.
"We were actually interested in looking at what was the impact of prostate cancer on sexual quality of life for female partners of patients," says Stacy Loeb, MD, MSc, PhD (hon).
"I think it requires the adequate staff, and then also the development of a practice pattern for how chaperones are used," says Ellen Cahill, MD.
Dhingra discusses the utility of PSMA-PET imaging when treating patients with prostate cancer.
Panelists discuss how metastatic castration-sensitive prostate cancer (mCSPC) is defined by its sensitivity to androgen deprivation therapy, while metastatic hormone-sensitive prostate cancer (mHSPC) emphasizes the cancer’s responsiveness to hormone treatment, highlighting the nuanced differences in patient management strategies.
"Most of us are focusing on our healthspan and our lifespan, but we also need to think about our sexspan," says Mohit Khera, MD, MBA, MPH.
"We wanted to study if Dupuytren's contracture has any effect at all in Xiaflex treatment," says Muhammed A. Moukhtar Hammad, MBBCh.
"We had 66 respondents, and 48% of those did say that they had functionally limiting pelvic pain...for 14 days out of a given month at least," says Sarah Ponce.
"I think it's really important when we're prescribing any medication to our patients to really have a good idea of what they can expect," says Evan Panken, MD.
